Cargando…
Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines
BACKGROUND: To explore the activity of dasatinib alone and in combination with gemcitabine and docetaxel in uterine leiomyosarcoma (uLMS) cell lines, and determine if dasatinib inhibits the SRC pathway. METHODS: SK-UT-1 and SK-UT-1B uLMS cells were treated with gemcitabine, docetaxel and dasatinib i...
Autores principales: | Lopez-Acevedo, Micael, Grace, Lisa, Teoh, Deanna, Whitaker, Regina, Adams, David J, Jia, Jingquan, Nixon, Andrew B, Secord, Angeles Alvarez |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877815/ https://www.ncbi.nlm.nih.gov/pubmed/27231555 http://dx.doi.org/10.1186/2053-6844-1-2 |
Ejemplares similares
-
Grade 4 Pneumonitis in a Patient Treated with a Combination of Gemcitabine and Docetaxel for Recurrent Leiomyosarcoma of the Uterus
por: Wang, Connor, et al.
Publicado: (2020) -
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
por: Chang, Alex Y, et al.
Publicado: (2013) -
Uterine Leiomyosarcoma
por: Byar, Katherine L., et al.
Publicado: (2022) -
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
por: Seddon, Beatrice, et al.
Publicado: (2015) -
Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)